SEHK:2142Biotechs
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?
HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and development of biologic drugs.
See our latest analysis for HBM Holdings.
Against this backdrop, HBM Holdings has been volatile, with the share price falling 1.74% over the past day but posting a 23.26% 1 month share price return. The 3 year total shareholder return is very large, signalling strong...